A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

Anna Kramvis, Kyong Mi Chang, Maura Dandri, Patrizia Farci, Dieter Glebe, Jianming Hu, Harry L.A. Janssen, Daryl T.Y. Lau, Capucine Penicaud, Teresa Pollicino, Barbara Testoni, Florian Van Bömmel, Ourania Andrisani, Maria Beumont-Mauviel, Timothy M. Block, Henry L.Y. Chan, Gavin A. Cloherty, William E. Delaney, Anna Maria Geretti, Adam GehringKathy Jackson, Oliver Lenz, Mala K. Maini, Veronica Miller, Ulrike Protzer, Jenny C. Yang, Man Fung Yuen, Fabien Zoulim, Peter A. Revill

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. Various stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed, and knowledge gaps in understanding and interpretation of HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses, opportunities and challenges of HBV biomarkers.

Original languageEnglish (US)
Pages (from-to)727-745
Number of pages19
JournalNature Reviews Gastroenterology and Hepatology
Issue number11
StatePublished - Nov 2022

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook'. Together they form a unique fingerprint.

Cite this